ACKR3 and cancer: The MAPK pathway is an important target for inhibiting tumour progression and angiogenesis,32 and our results in the present study suggest that antagonizing CXCR7 might be a potent complementary strategy for inhibiting MAPK during anti‐angiogenic therapy in cancer.